Due to frequent mutations in certain cancers, FGFR3 gene is considered as an oncogene. However, in some normal tissues, FGFR3 can limit cell growth and promote cell differentiation. Thus, FGFR3 action appears paradoxical.
FGFR3 expression was forced in pancreatic cell lines. The receptor exerted dual effects: it suppressed tumor growth in pancreatic epithelial-like cells and had oncogenic properties in pancreatic mesenchymal-like cells. Distinct exclusive pathways were activated, STATs in epithelial-like cells and MAP Kinases in mesenchymal-like cells. Both FGFR3 splice variants had similar effects and used the same intracellular signaling. In human pancreatic carcinoma tissues, levels of FGFR3 dropped in tumors.
In tumors from epithelial origin, FGFR3 signal can limit tumor growth, explaining why the 4p16.3 locus bearing FGFR3 is frequently lost and why activating mutations of FGFR3 in benign or low grade tumors of epithelial origin are associated with good prognosis. The new hypothesis that FGFR3 can harbor both tumor suppressive and oncogenic properties is crucial in the context of targeted therapies involving specific tyrosine kinase inhibitors (TKIs). TKIs against FGFR3 might result in adverse effects if used in the wrong cell context.
The fibroblast growth factor receptor 3 (FGFR3) belongs to the family of tyrosine kinase receptors . FGFR activation induces proliferation and migration in many physiological situations, but in some cell types, FGF signaling induces differentiation and/or cell proliferation inhibition and/or cell death. Deregulation of FGF signaling in carcinogenesis has been widely explored. On one hand, it is now well-established that FGFs and FGFRs can be oncogenic through different intracellular molecular targets leading to increased cell proliferation, cell survival, angiogenesis and promotion of cell migration and invasion. On the other hand, FGF tumor suppressive effects are more and more documented, in particular for FGFR2 signaling (reviewed in ). In normal tissues, FGFR3 might have a negative impact on cell growth, the most striking example being its function during bone development confirmed by activating mutations in human skeletal disorders. In growth plates of the developing long bones, FGFR3 negatively controls cell proliferation and induces chondrocyte apoptosis in late embryonic stages (reviewed in ). In the same way, mice lacking FGFR3 receptor showed extended bone length  and transgenic mice with activating mutations are dwarfs . In pancreatic and intestinal mouse tissues, we previously showed that FGFR3 has a negative impact on normal epithelial cell proliferation [5, 6]. In cancers, activating somatic mutations of FGFR3 were first characterized in bladder cancer and cervix cancer . In bladder cancers, mutations occur preferentially in non-muscle invasive disease and much less commonly in muscle-invasive lesions, suggesting that these alterations could be linked to a favorable course of the disease in non invasive papillary bladder cancer . Seborrheic keratoses and epidermal nevi, benign tumors of the skin, can also present activating mutations of FGFR3 (reviewed in ). In colorectal tumors, mutations were possibly inactivating mutations, while decreased expression of FGFR3 was found in colorectal cancer cell lines [10, 11] and tumors . Conversely, multiple myelomas can harbor a t(4:14) intergenic translocation bringing FGFR3 gene under the control of the strong immunoglobulin heavy chain promoter, participating in tumor progression .
Despite contradictory results in different tumor types and models, to date, FGFR3 pathway is considered to be oncogenic in human tumors, by contrast to the situation in normal development of the long bones. Moreover, little is known on FGFR3 actions in pancreatic tumors. We explored the actions of FGFR3 in modulating pancreatic cancer cell behavior.
FGFR3 overexpression has tumor suppressive effects
FGFR3 is expressed as two splice variants, the FGFR3-IIIb and FGFR3-IIIc. Forced expression of either splice variants was performed in two pancreatic ductal adenocarcinoma (PDAC) cell lines: the Capan-2 and the BxPC-3 pancreatic cells. The capacities of the cells to form clones in low density cultures was increased by both FGFR3-IIIb and IIIc as compared to the control condition, except for the IIIb splice variant in the BxPC-3 cells (Table 1). Interestingly, this effect was maintained when cells were transduced with a FGFR3-IIIc cDNA lacking tyrosine kinase activity (K508M mutation, FGFR3-IIIc-KD, Table 1). Interestingly however, the areas of the colonies were smaller with FGFR3 overexpression but not with FGFR3-IIIc-KD (Table 1). Noticeably, clones overexpressing high levels of FGFR3 appeared much smaller than clones expressing lower levels as attested by ZsGreen protein fluorescence intensity (Figure 1A, left panel). Mean fluorescence intensities were lower for cells transduced with active forms of FGFR3 (Figure 1A, right panel). Thus, FGFR3 promoted colony formation of pancreatic cells, but clone expansion was reduced. This latter effect depended on active FGFR3 tyrosine kinase. Furthermore, forced expression of both FGFR3 splice variants in Capan-2 and BxPC-3 cells reduced the cell proliferation (Figure 1B). Flow cytometry analyses did not evidence major differences in the distributions of cells in the cell cycles phases (Additional file 1: Figure S1), but a significant and important accumulation of cells in sub-G1 was observed, suggesting that FGFR3 induced apoptosis (Additional file 1: Figure S1 and Figure 1C).
FGFR3 impact in pancreatic tumour cell lines
Colony formation (Ratio/CT)
Colony area (μm2)
Migration (number of cells)
Senescent cells (%)
Tumour mass (mg)
Colony formation (Ratio/CT)
Colony area (mm2)
Tumour mass (mg)
Colony formation (Ratio/CT)
Colony area (mm2)
Migration (number of cells)
Senescent cells (%)
Tumour mass (mg)
Colony formation (Ratio/CT)
Colony area (mm2)
Tumour mass (mg)
1 ± 0.13
19.3 ± 5.0
997 ± 6
24.4 ± 5.3
203 ± 37
1 ± 0.18
24.2 ± 15.1
42 ± 0.01
1 ± 0.004
13.8 ± 4.7
98 ± 2
8.6 ± 1.9
21 ± 3
1 ± 0.05
9.9 ± 9.2
59 ± 39
1.38 ± 0.06*
9.1 ± 1.5*
1524 ± 26***
35.7 ± 3.9**
110 ± 12*
0.97 ± 0.10
15.9 ± 11.9**
1.52 ± 0.18**
17.0 ± 4.6**
346 ± 9***
4.7 ± 1.9***
292 ± 133*
1.28 ± 0.04*
21.5 ± 14.1***
137 ± 51*
1.52 ± 0.27*
6.3 ± 1.5**
2050 ± 18***
32.4 ± 5.5*
111 ± 14*
1.37 ± 0.04*
12.7 ± 9.7***
23 ± 0.01*
1.28 ± 0.17*
23.7 ± 8.1***
515 ± 22***
5.0 ± 1***
367 ± 113**
1.23 ± 0.04*
22.8 ± 14.6***
138 ± 39*
1.21 ± 0.05*
15.7 ± 11.1
1492 ± 10***
16.9 ± 3.26*
212 ± 71
1.26 ± 0.04**
20.9 ± 14.2
1.55 ± 0.12*
15.1 ± 8.7**
Cells were transduced to obtain 70% of transduced cells as analyzed by flow cytometry. For colony formation assays, 500 cells were plated in 10 mm dished in triplicates. Dishes were processed for violet crystal staining and blind counted. Colony areas were measured with Image J software. Senescence was detected as indicated in the methods section. Senescence was not detectable in BxPC-3 and PANC-1 cells. Results are reported as means ± SD except for tumour masses ± SEM. *: p < 0.05 **: p < 0.01 ***: p < 0.001 as compared to control. Ratio/CT: results are expressed as ratio over the control condition. ND: not done.
Over time Capan-2 cells that appeared viable were still detectable by light microscopy. Viable cells stopping proliferation, but not proceeding to apoptosis, could be undergoing senescence. Acidic beta-galactosidase staining associated with the senescent phenotype in numerous studies (reviewed in ). It was significantly increased in FGFR3-IIIb and -IIIc overexpressing cells compared with the controls (Table 1, and Additional file 2: Figure S2A) in Capan-2 cells, but not in BxPC-3 cells where senescence did not seem to occur at all.
To further test whether the effects of FGFR3 seen in vitro were valid in vivo, transduced cells, sorted by flow cytometry were xenografted in immune-compromised mice and tumor progression was examined. Very interestingly, overexpression of both FGFR3-IIIb and –IIIc inhibited Capan-2 and BxPC-3 tumor growth (about 2-fold decrease, Table 1). Noticeably, establishment of single clones overexpressing FGFR3-IIIc in Capan-2 cells showed that tumor growth inhibition was dependent on FGFR3-IIIc expression levels (R2 about 0.87, Additional file 3: Figure S3). The tumor masses were not different from controls when Capan-2 cells overexpressed FGFR3-IIIc-KD, suggesting that the negative impact on tumor progression depended on FGFR3 tyrosine kinase activity (Table 1).
FGFR3 impacts pancreatic epithelial- and mesenchymal-like cells differently
FGFR3 behaved as a tumor suppressor in pancreatic cells, which was contradictory with its proposed oncogenic properties described in the literature. To further confirm this surprising result, both splice variants were overexpressed in two additional pancreatic adenocarcinoma cell lines. As observed for the two previous cell lines, colony formation was induced by FGFR3 in both the Mia PaCa-2 and PANC-1 cells, independently of FGFR3-IIIc kinase activity for the PANC-1 cells (Table 1). However, this time, colony size was unexpectedly significantly enhanced even when the FGFR3-IIIc lacked kinase activity (Table 1). This feature was in agreement with increased proliferation (Figure 1D). In Mia Paca-2 cells, cell cycle analysis by flow cytometry showed that cells in S phase were about 2-fold more numerous in the presence of FGFR3 forced expression (Additional file 1: Figure S1). Senescence was not detected in PANC-1 cells and was low but decreased in Mia PaCa-2 cells (Table 1 and Additional file 2: Figure S2B). In vivo tumor formation confirmed the in vitro data since overexpression of both FGFR3-IIIb and –IIIc strongly promoted PANC-1 (2-3-fold increase, Table 1) and even more the Mia PaCa-2 (13-17-fold increase, Table 1) tumor growth.
It seemed that FGFR3 impacted cancer cell clonogenic properties independently of its kinase activity. We further tested Capan-2 cell migration capacities. Again cell migration was increased by FGFR3, independently of its kinase activity (Table 1).
The different responses of the cells could be linked to various endogenous FGFR3 levels, before over-expression. Western-blots showed that BxPC-3 cells expressed the highest levels of the receptor, and the Mia PaCa-2 cells the lowest (Figure 2A). The two other cell lines displayed similar intermediate FGFR3 protein levels, but opposite behavior in response to FGFR3 forced expression. RT-qPCRs further showed that FGFR3-IIIb isoform was more abundant, except for the Mia PaCa-2 cells (Figure 2B). In addition total FGFR3 was detected by immunofluorescence in the cell lines, and we noticed that it had nuclear localization in PANC-1 and MiaPaCa-2 cells, but not in Capan-2 or BxPC-3 cells (Additional file 4: Figure S4). In Normal Human Keratinocytes (NHEK), signal was detected throughout the whole cells. Thus total FGFR3 levels or distinct FGFR3 splice variant relative abundance could not explain the opposite phenotypes.
FGFR-IIIb isoform is preferentially expressed in cells of epithelial origin and FGFR-IIIc isoforms in mesenchymal cells . RT-qPCRs were performed to assess the levels of expression of E-cadherin and vimentin, markers of epithelial and mesenchymal cells, respectively (Figure 2C). Capan-2 and BxPC-3 cells displayed epithelial characteristics (strong E-cadherin expression, almost no vimentin expression). The Mia PaCa-2 line was mesenchymal-like (no E-cadherin expression and strong vimentin expression) and PANC-1 s displayed an intermediate phenotype since they still expressed some E-cadherin but did express high levels of vimentin. These cells retained characteristics of epithelial cells in terms of cell shape, like the Capan-2 and BxPC-3 cells, while the Mia PaCa-2 cells resembled fibroblasts (Figure 2D). Thus, our experimental cell models were distinguishable in three categories: the epithelial-like cells (BxPC-3 and Capan-2), the mesenchymal-like cells (Mia PaCa-2) and cells with intermediate phenotype (PANC-1).
In light of this data, it appeared that in epithelial-like pancreatic cells (BxPC-3 and Capan-2), FGFR3 had tumor suppressive effects, while in cells with mesenchymal cell features (Mia PaCa-2 and PANC-1), FGFR3 had oncogenic effects.
To further explore the impact of FGFR3 in epithelial cells, the proliferation of the mouse pancreatic epithelial beta cell line BTC  was assessed in the presence of a neutralizing anti-FGFR3 antibody or with FGFR3-IIIc splice overexpression in vitro. The inhibition of FGFR3 activity increased BTC cell proliferation, while transient forced expression of FGFR3-IIIc significantly diminished BTC cell expansion (Figure 3A). When BTC cells overexpressing FGFR3-IIIc were xenografted in immune deficient mice, tumor progression was strongly inhibited as compared to control cells (Figure 3B and Additional file 5: Figure S5). This suggests that as in pancreatic adenocarcinoma cell lines with epithelial phenotype, FGFR3 limits beta cell growth.
FGFR3 ligands are differentially expressed in pancreatic cell lines
The different responses of the cell lines to FGFR3 signal could be related to distinct status in available FGFs. We performed all the in vitro experiments in complete media, without modulating the levels of FGFs. The reason was that all the PDAC cell lines expressed endogenous FGFs that could bind either splice variants of the receptor (Additional file 6: Figure S6A). Indeed, RT-qPCR aimed to evaluate the relative levels of known ligands for FGFR3 in the parental cells showed that FGF4 and FGF23 were not detectable. CAPAN2 cells expressed FGF17 and FGF18, also present in the MIAPACA2 cells at similar levels. Interestingly however, distinct profiles were obtained for other FGFs. Strikingly, MIAPACA2 and PANC1 cells expressed very high levels of FGF2 mRNAs, which were almost not detectable in the epithelial-like cells. Moreover, the CAPAN2 cells expressed FGF9, which was also detected at a lower level in BXPC3s, but not the two other cell lines. Importantly, FGF2 and FGF9 levels were increased in cells overexpressing FGFR3 (Additional file 6: Figure S6B), suggesting that autocrine loops in parental cell lines are reinforced with FGFR3 forced expression.
Thus it seems that distinct autocrine loops are present in the PDAC cell lines for FGFR3. FGF2 was clearly associated with the MIAPACA2 and the PANC1 cells, but not cells with an epithelial phenotype.
FGFR3 signaling is different in pancreatic epithelial and mesenchymal-like cells
In the presence of the ligand, the dimerization of the receptor triggers FGFR transphosphorylations, to create docking sites for downstream signaling factors activating pathways such as RAS and the downstream MAP Kinases, the PI3Kinase/Akt pathway or the Signal transducer and activator of Transcription (STAT) pathway. The protein extracts of tumors overexpressing FGFR3 with the strongest and opposite phenotypes (Capan-2 and Mia PaCa-2 cells) were analyzed by western-blotting. Active JNKs, detectable only in Capan-2 cells, were unchanged (not shown). In FGFR3-Capan-2 cells, other activated MAP Kinases were unchanged (Figure 4), but in Mia PaCa-2 cells both ERKs and P38 were over-activated (Figure 4). Conversely, phosphorylation of STATs was found strongly increased by FGFR3 overexpression in Capan-2 cells but was not detected in Mia PaCa-2 cells. This effect in Capan-2 cells disappeared when transduced with FGFR3-IIIc-KD. Although AKT was present in all the tumor extracts, no changes were observed in activated AKT (not shown). The proteins p21 and p27, downstream effectors of FGFR3 in chondrocytes  were mildly increased in FGFR3-Capan-2 tumors (Figure 3), but not in the Mia PaCa-2 (not detectable). Since apoptosis was found up-regulated in FGFR3-Capan-2 cells, we looked at apoptosis markers. BAX signal was stronger in FGFR3 conditions, while BCL2 remained unchanged (Figure 4). Thus the balance of anti-apoptotic/pro-apoptotic proteins was moved towards apoptosis. This was further confirmed by increased levels of both cleaved caspase 9 and caspase 3 (Figure 4). In Mia PaCa-2 s, there was no obvious change in the anti-apoptotic/pro-apoptotic balance and cleaved caspases were not detectable (Figure 4). Senescence often depends on p53 activation or stabilization. The Capan-2 cells were the only cell line in our hands bearing wild type copies of TP53. Total p53 and Phospho-p53 were not changed in FGFR3 overexpressing cells (not shown).
Finally, autophagy can promote proliferation or apoptosis. LC3B protein conversion status was evaluated. Both LC3B-I and LC3B-II peptides were detected, indicating that autophagy is active in Capan-2 cells. However, FGFR3 did not induce any change in LC3B-I cleavage (band intensity of LC3B-II/LC3B-I, Figure 4B). In Mia PaCa-2 cells, the basal levels of both LC3B forms were increased in the presence of FGFR3 overexpression, together with the rate of LC3B-I cleavage (Figure 4). This suggests that FGFR3 promoted autophagy in the Mia PaCa-2 cells.
Thus, it seemed that in epithelial-like cells FGFR3 activated STATs but not ERKs and in mesenchymal cells, it was the opposite. To further explore this point, western-blots were performed with tumor extracts from BxPC-3 and PANC-1 cells. As in Capan-2 cells, BxPC-3 cells showed increased STATs activation and unchanged P-ERK levels (Additional file 7: Figure S7). Surprisingly, in PANC-1, none of the tested signaling seemed affected by FGFR3 forced expression, despite phenotypes similar to what was observed in the MiaPaCa-2 cells (Additional file 7: Figure S7). P-ERKs and P-JNKs were evidenced but not modulated and P-p38 was undetectable even if p38 was present (Additional file 7: Figure S7). In the same way although P-STAT1 proteins were detected in the PANC-1 cell extracts, they were not induced by either FGFR3 splice variant. BAX and Bcl-2 were unchanged. Thus, in PANC-1 cells, the oncogenic effect of FGFR3 was evidenced, but it clearly depended on intracellular signals different from those in the Capan-2 or the MiaPaCa-2 cells. Cell proliferation capacities are strongly modulated by phosphorylation of RB1 protein. This protein is detected and active in many PDAC cell lines, including the ones used in the present report . RB1 phosphorylation at serine 795 was induced in PANC1 cells overexpressing FGFR3 but not in Capan-2 cells where it was detectable or MIAPACA2 cells where it was undetectable, suggesting that RB1 activity was diminished in PANC1 cells (Additional file 7: Figure S7). In the same way, CREB phosphorylation was induced in PANC1 cells and was undetectable in CAPAN2 cells or in MIAPACA2 cells.
Thus, FGFR3 intracellular partners were the same in the epithelial-like cancer cells, but different in the mesenchymal-like cells.
FGFR3 expression is downregulated in human pancreatic tumor tissues
To gain insight into the impact of FGFR3 signalling pathway specifically in pancreatic cancers, pancreatic cancer tissues were analyzed for the levels of expression of the receptor compared to normal pancreatic tissue.
Strong FGFR3 immune signal was found in normal pancreatic islets, while a weak signal was present in the exocrine tissue (Figure 5a,b). FGFR3 was co-localized with insulin-positive cells, but was also present in non beta cells in islets (Figure 5c). Both splice variants appeared to be equally abundant in the normal pancreas (Additional file 8: Table S1).
In cancer tissues, we found a significant decrease of FGFR3 RNAs in PDAC as compared to normal pancreas, regardless of the splice variant, which balance did not change (Additional file 8: Table S1). In tissue microarrays, when compared to FGFR3 signal intensity in normal pancreas (high in islets, weak in ducts), about 70% of the pancreatic endocrine carcinomas showed partial or total loss of FGFR3 signal (Figure 5d-f). 63% of the intraductal papillary mucinous neoplasms and 30% of the pancreatic ductal adenocarcinomas showed total loss of FGFR3 signal. Some of the two latter cancer tissues displayed areas with strong staining, but it was always highly heterogeneous (Figure 5g-l), some regions totally lacking FGFR3, on the same sections (Figure 5i and 5l). Thus, FGFR3 transcripts and protein seemed to be lost in a non negligible proportion of pancreatic tumors, especially in endocrine tumors.
The impact of FGFR3 mutations in various tumors can be revisited in light of the present study
Early published data converged towards oncogenic properties of FGFR3. Indeed, in multiple myelomas, the chromosomal translocation t(4;14)(p16.3;q32) results in ectopic overexpression of FGFR3 . Further, FGFR3 was considered as an oncogene in hematopoietic cell models  and in 3T3 fibroblast, but not in the T24 epithelial cells . In other soft tissue tumors such as synovial carcinomas or rhabdomyosarcomas, FGFR3 was involved in the malignant phenotype [19, 20]. Results in Mia PaCa-2 cells (this work) and SW480  support the notion that in tumors originating from mesenchymal cells, FGFR3 is an oncogene.
However, puzzling observations were previously unexplained and even incompatible with FGFR3 being an oncogene. First, the receptor has a negative regulatory role during bone development. In colorectal cancers, a group noticed frequent inactivation of the receptor or downregulation of the protein . Importantly, frequent loss of heterozygosity of the chromosomal region carrying FGFR3 gene (the 4p16.3 locus) has been characterized, suggesting that this region carries a tumor suppressor gene . In that context, it was surprising to find FGFR3 as an oncogene in this locus. FGFR3 expression was reduced in almost 60% of cervix tumors and when it was increased, it was in tumors of good prognosis . Later on, critical data showed a significant association of loss of FGFR3 and tumor stage in high grade urothelial bladder cancers . Accordingly, FGFR3 activating mutations were associated with early, non invasive, low grade papillary tumors and never found in carcinomas in situ . Consequently, active mutants of FGFR3 are now associated with low grade tumors in urothelial cancers and possible loss of heterozygosis at FGFR3 locus might accompany the switch to higher grades (reviewed in ). In the same way, in seborrheic keratoses and epidermal nevi, benign tumors of the skin very rarely progressing into malignant disease, also present high rates of activating mutations of FGFR3 (reviewed in ), suggesting a protective role of increased FGFR3 in these models, of epithelial origin. Our data support the concept that FGFR3 signal in epithelial context might actively participate to limit loss of proliferation control, and inhibit the switch to malignant disease. In pancreatic cancer, this hypothesis is in agreement with the loss of expression found in RNA and tissue sections of pancreatic cancers (the present work). It would be very interesting to check the status of cell phenotypes in the same tumors to determine the proportion of lesions which have undergone the epithelial to mesenchymal transition. We did not have the clinical parameters of the patients from whom the lesions came from. Additional experiments are needed to determine whether loss of FGFR3 signal correlates with bad prognosis of the disease. Moreover, it would be interesting to test the possibility that pancreatic lesions with mesenchymal phenotype retain FGFR3 expression. In colorectal cancer models , authors could not explain the loss of FGFR3 expression in human tumors since they believed that FGFR3 was an oncogene. However, they found, like us, a downregulation of FGFR3 expression in colorectal cancers. They used several colorectal cancer cell lines to evaluate FGFR3 impact on growth and migration. They could not obtain FGFR3 transfectants with the CaCo2 cell line and observed the HCT116 cells being inhibited by FGFR3 overexpression. Opposite phenotype was reported in the SW480 cells, and the main conclusions of the report were drawn based on this cell line only. Interestingly, HCT116 cells express high levels of E-cadherin and low levels of vimentin , while SW480 cells do not express E-Cadherin , but vimentin . It is possible that CaCo2 cells died in the presence of FGFR3 forced expression. We ourselves encountered difficulties in obtaining single Capan-2 or BTC clones with FGFR3-IIIc overexpression. Thus the conclusions of Sonvilla et al. might be reformulated in light of our results.
Molecular mechanisms of FGFR3 signals in PDAC cells
FGFR3 oncogenic effect seemed to be conveyed by MAP kinases activation in the Mia PaCa-2 cells, even if several studies report that KRAS is mutated in that cell line, as in most PDAC cells. It means that an alternative pathway transmitted FGFR3 signal in those cells to over-activate MAP kinases. This activation but not that of STATs is similar to what was found in multiple myelomas . The differences in percentages found in flow cytometry analyses could not explain the differences in cell counts. It is possible that the higher rate of autophagy contributes to cell growth promotion in these cells, as suggested by variations in LC3B levels and cleavage rate. This hypothesis needs further analysis in future. Interestingly, in PANC-1 cells FGFR3 had oncogenic properties but signaling was different to what was evidenced in Mia PaCa-2s. Alternative pathways might occur depending on intracellular available adaptors and lead to phenotypes with different intensities as observed in this study.
Distinct autocrine loops were evidenced in PDAC cells. It is possible that opposite effects were FGF-dependent (FGF2 for the oncogenic effect and FGF9 for the tumor suppressive effect), the role of FGF2 being supported by previous studies ( for example) but more work is needed to test the dependency of FGFR3 to FGFs.
The most relevant finding of this study is the tumor suppressive properties of FGFR3 in pancreatic ductal adenocarcinoma epithelial cells. In the growth plates of developing long bones, FGFR3 negatively controls cell proliferation and induces chondrocyte apoptosis in late embryonic stages, noticeably through STATs activation (reviewed in ). This, together with induction of senescence could account for the loss of cell numbers observed in our proliferation assays. It has been shown recently that FGFR3-IIIc can induce premature reversible senescence in chondrocytes . Authors found, like us, that p53 was active in their cells but that FGFR3-induced senescence was independent of p53. In our hands, the main difference between the epithelial-like and the mesenchymal-like cell response to FGFR3 signal was the activation of STATs, which can elicit senescence response independent of p53 . Since we found p21 modestly induced in FGFR3 overexpressing cells, it is possible that activated STATs directly controlled CDKN1A gene promoter, as earlier described .
The present data raise the possibility that FGFR3 has biphasic effects during multistage carcinogenesis in carcinomas, acting first as a tumor suppressor through oncogene-induced senescence via STATs activation and apoptosis enhancement. In this context, FGFR3 loss would help tumor progression. Alternatively, after additional mutations have occurred in the developing tumor, decoupling FGFR3 from its canonical inhibitory pathway (STATs), FGFR3 signal might be redirected to other intracellular factors, promoting tumor progression (Figure 6). In the same way, epithelial to mesenchymal phenotype transition would reveal FGFR3 as an oncogene by coupling the receptor to MAP kinases pathways. This model supports a new aspect of FGFR3 function, explaining why in epithelial cancers FGFR3 activating mutations were associated with good prognosis tumors whereas in soft tissue cancers, FGFR3 promoted tumor progression. More importantly, this work might open a new debate on the use of FGFR3 inhibitors in anticancer therapy.
Materials and methods
Animals, pancreatic cell lines and antibodies, tissue specimens
The 6 to 8 week-old NOD/Shi-SCID IL2Rγnull mice were produced and housed at the University Bordeaux Segalen animal facility A2, according to the rules and regulations of the Institutional Animal Care and Use Committee (agreement number A33063916).
The BxPC-3 and Capan-2 cells were provided by Joel Tardive-Lacombe (INSERM U624, Marseille, France). The cells were maintained in RPMI (Invitrogen, Saint Aubin, France) with 10% Fetal Calf Serum (FCS, Invitrogen) with Penicillin/Streptomycin 1/100 (Invitrogen). Mia PaCa-2 and PANC-1 cells were purchased from the ATCC (Teddington, United Kingdom) and maintained in DMEM with 10% FCS and 1/100 Penicillin/Streptomycin (Invitrogen). The BTC cells were obtained from Simon Efrat (Tel Aviv University, Israel).
The following antibodies were used: FGFR3 (SIGMA-ALDRICH, Lyon, France), Phospho-p44/p42 MAPK, p44/p42 MAPK, Phospho SAPK/JNK, SAPK/JNK, Phospho Akt, Akt, Caspase-3, Caspase-9, Phospho-STAT1, Phospho-STAT3, BAX, p21, p27, Phospho-p38, p38, GAPDH (all from Cell Signaling, Saint-Quentin en Yvelines, France).
Tissue specimens were obtained with informed consent from all patients. Tissue arrays were stained with anti-FGFR3 antibody using the Duolink® system (Eurogentec, Angers, France) with which primary antibody detection depends on a very specific PCR system, giving a punctuated brown signal.
Vector construction and transduction of cells
The pMND-IRES2-ZsGreen1 was used as recipient vector of all the constructs. FGFR3-IIIb and FGFR3-IIIc and FGFR3-IIIIc-K508M were kindly provided by David Cappellen (EA2406, Univ. Bordeaux, France) and Pavel Krejci (Medical Genetics Institute, Los Angeles, California), respectively and cloned upstream the IRES sequence. FGFR3-IIIb and FGFR3-IIIc overexpressing cell lines were obtained by transduction of lentiviral plasmids. Control cells were produced by transduction of the empty pMND-IRES-ZsGreen vector. For xenografts, transduced cells were sorted by a BD FACS ARIA cell sorter (BD Biosciences, Le Pont de Claix, France).
Isolation of RNA, cDNA synthesis, and quantitative real-time PCR analysis
Total RNA was isolated using Trizol® and treated by DNAse according to the manufacturer’s instructions (Invitrogen and Ambion, Saint Aubin, France). cDNAs were synthesized using Reverse transcriptase cDNA synthesis kit (Roche Applied Science, Meylan, France). Quantitative real-time PCR assays were performed with the SYBR® Green Master Mix and carried out on a Stratagene MX-3005P system (Stratagene, Massy, France). Sequences of primers can be provided upon request.
Protein extraction and western-blotting
Protein extracts and western blotting were performed as already described .
Cell cycle analysis
Non synchronized subconfluent cells were harvested and washed twice with PBS then fixed with 70% ethanol in PBS overnight at 4°C. Cells were washed twice with PBS and incubated with a mix containing RNAse (1 mg/ml, SIGMA-ALDRICH) and PBS-Propidium iodide (0.5 μg/ml, SIGMA-ALRICH) for 15 min. The samples were examined on a BD FACS CANTO II apparatus and the data were analyzed with BD FACSDiva software (BD Biosciences, Le Pont de Claix, France).
SA-β-galactosidase activity was observed with an inverted Nikon Microscope (Eclipse Ti Nikon, Champigny sur Marne, France). Pictures were taken with the NIS-Elements Nikon software. For SA-β-galactosidase positive cell quantification, cells were counted on twenty separate fields and the means of (100*number of blue cells/number of total cells) were calculated corresponding to the percent of SA-β-galactosidase positive cells. The numbers of counted cells were for the Capan-2: CTRL (1914), FGFR3-IIIb (2809), FGFR3-IIIc (3159), FGFR3-IIIc-KD (1687); For the MIAPAC2: CTRL (2345), FGFR3-IIIB (2718), FGFR3-IIIc (2563).
Xenografts of PDAC cell lines
Groups of at least 5 mice were anesthetized with isoflurane. 8×105 cells (4×105 for BTC cells) in 100 μl serum-free medium were injected in the right flanks. When tumors were visible, measures with a calibrator were done 3 times a week. Tumors were resected and weighed at various times after the initial grafts, according to the cell line.
In vitro results are expressed as mean ± SD. Results in vivo are expressed as mean ± SEM. Statistical tests were performed with unpaired, bilateral Student’s t tests.
We are indebted to the Tumothèque of Bordeaux for providing us with PDAC RNA extracts. We are very grateful to Jean-Max Pasquet for his expertise on senescence analysis, to the Plateforme d’Histologie of the Université Bordeaux Segalen and to Alice Bibeyran from the Plateforme of vectorologie of Université Bordeaux Segalen. We also thank the staff from the Animaleries of the Université Bordeaux Segalen for their technical support, Pierre Costet for his support in setting up the xenograft models, and Aline Costet for her administrative help. This work was supported by grants from the Ligue contre le cancer (Comité Dordogne and Comité Landes), the Institut National du Cancer (INCa), France and funding from the SFR Transbiomed (formerly IFR66).
INSERM U1035, Université Bordeaux Segalen
Plate-forme de vectorologie, Université Bordeaux Segalen
Animalerie A2, Université Bordeaux Segalen
EA2406 Université Bordeaux Segalen
CHU de Bordeaux
Tumorothèque de Montpellier
Turner N, Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010, 10: 116-129. 10.1038/nrc2780View ArticlePubMed
Li C, Chen L, Iwata T, Kitagawa M, Fu XY, Deng CX: A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet. 1999, 8: 35-44. 10.1093/hmg/8.1.35View ArticlePubMed
Arnaud-Dabernat S, Kritzik M, Kayali AG, Zhang YQ, Liu G, Ungles C, Sarvetnick N: FGFR3 is a negative regulator of the expansion of pancreatic epithelial cells. Diabetes. 2007, 56: 96-106. 10.2337/db05-1073View ArticlePubMed
Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999, 23: 18-20.PubMed
Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A, Carrato A, Serra C, Malats N, Real FX: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006, 24: 3664-3671. 10.1200/JCO.2005.05.1771View ArticlePubMed
Hernandez S, Toll A, Baselga E, Ribe A, Azua-Romeo J, Pujol RM, Real FX: Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol. 2007, 127: 1664-1666.PubMed
Jang JH, Shin KH, Park YJ, Lee RJ, McKeehan WL, Park JG: Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Res. 2000, 60: 4049-4052.PubMed
Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997, 16: 260-264. 10.1038/ng0797-260PubMed CentralView ArticlePubMed
Efrat S, Fusco-DeMane D, Lemberg H, al Emran O, Wang X: Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci U S A. 1995, 92: 3576-3580. 10.1073/pnas.92.8.3576PubMed CentralView ArticlePubMed
Plath T, Peters M, Detjen K, Welzel M, von Marschall Z, Radke C, Wiedenmann B, Rosewicz S: Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J Natl Cancer Inst. 2002, 94: 129-142. 10.1093/jnci/94.2.129View ArticlePubMed
Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B, Hawley TS, Hawley RG, Stewart AK: The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood. 2001, 97: 2413-2419. 10.1182/blood.V97.8.2413View ArticlePubMed
Bernard-Pierrot I, Brams A, Dunois-Larde C, Caillault A, de Medina SGD, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D, Radvanyi F: Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 2006, 27: 740-747.View ArticlePubMed
Hirotsu M, Setoguchi T, Matsunoshita Y, Sasaki H, Nagao H, Gao H, Sugimura K, Komiya S: Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer. 2009, 101: 2030-2037. 10.1038/sj.bjc.6605407PubMed CentralView ArticlePubMed
Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, Shima Y, Nagayama S, Katagiri T, Nakamura Y: Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res. 2005, 11: 2702-2712. 10.1158/1078-0432.CCR-04-2057View ArticlePubMed
Sibley K, Cuthbert-Heavens D, Knowles MA: Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 2001, 20: 686-691. 10.1038/sj.onc.1204110View ArticlePubMed
Dai H, Holm R, Kristensen GB, Abeler VM, Borresen-Dale AL, Helland A: Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas. Anal Cell Pathol. 2001, 23: 45-49.View ArticlePubMed
Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR: FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol. 2006, 32: 231-237. 10.1016/j.ejso.2005.11.018View ArticlePubMed
Zieger K, Marcussen N, Borre M, Orntoft TF, Dyrskjot L: Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. Int J Cancer. 2009, 125: 2095-2103. 10.1002/ijc.24619View ArticlePubMed
Knowles MA: Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007, 25: 581-593. 10.1007/s00345-007-0213-4View ArticlePubMed
Roger L, Jullien L, Gire V, Roux P: Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci. 2010, 123: 1295-1305. 10.1242/jcs.061002View ArticlePubMed
Hayashida Y, Honda K, Idogawa M, Ino Y, Ono M, Tsuchida A, Aoki T, Hirohashi S, Yamada T: E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res. 2005, 65: 8836-8845. 10.1158/0008-5472.CAN-05-0718View ArticlePubMed
McInroy L, Maatta A: Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun. 2007, 360: 109-114. 10.1016/j.bbrc.2007.06.036View ArticlePubMed
Ronchetti D, Greco A, Compasso S, Colombo G, Dell’Era P, Otsuki T, Lombardi L, Neri A: Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene. 2001, 20: 3553-3562. 10.1038/sj.onc.1204465View ArticlePubMed
Leung HY, Gullick WJ, Lemoine NR: Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994, 59: 667-675. 10.1002/ijc.2910590515View ArticlePubMed
Krejci P, Prochazkova J, Smutny J, Chlebova K, Lin P, Aklian A, Bryja V, Kozubik A, Wilcox WR: FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone. 2010, 47: 102-110. 10.1016/j.bone.2010.03.021PubMed CentralView ArticlePubMed
Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P, Hanzlikova H, Vancurova M, Barath P, Bartek J, Hodny Z: Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle. 2010, 9: 3085-3099. 10.4161/cc.9.15.12521View ArticlePubMed
Bellido T, O’Brien CA, Roberson PK, Manolagas SC: Transcriptional activation of the p21(WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem. 1998, 273: 21137-21144. 10.1074/jbc.273.33.21137View ArticlePubMed
Lafitte M, Rousseau B, Moranvillier I, Taillepierre M, Peuchant E, Guyonnet-Duperat V, Dubus P, Bedel A, de Verneuil H, Moreau-Gaudry F, Dabernat S: In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. Mol Cancer. 2012, 11: 81- 10.1186/1476-4598-11-81PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.